Eileen M. O'Reilly
艾琳·奥赖利
MD
Section Head, Hepatopancreaticobiliary Cancers; Winthrop Rockefeller Chair in Medical Oncology肝胰胆肿瘤科主任；温斯罗普·洛克菲勒医学肿瘤讲席教授
👥Biography 个人简介
Eileen M. O'Reilly, MD is Section Head for Hepatopancreaticobiliary Cancers at Memorial Sloan Kettering Cancer Center and holds the Winthrop Rockefeller Chair in Medical Oncology. She is one of the world's foremost clinical investigators in pancreatic and biliary tract cancers, having led or co-led pivotal trials that redefined practice including the POLO trial establishing olaparib maintenance in germline BRCA-mutated metastatic PDAC. Her research program encompasses hereditary susceptibility genes, DNA damage repair–targeted therapy, novel immunotherapy combinations, and early detection of pancreatic cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Olaparib Maintenance in BRCA-Mutated PDAC (POLO Trial)
Led the POLO phase III trial demonstrating that olaparib maintenance therapy significantly extended progression-free survival in patients with germline BRCA1/2-mutated metastatic PDAC who had not progressed during first-line platinum-based chemotherapy, resulting in FDA approval.
Hereditary Pancreatic Cancer and DNA Repair Pathways
Defined the prevalence and clinical significance of germline BRCA1, BRCA2, PALB2, and ATM alterations in pancreatic cancer, advocating for universal germline testing and shaping guidelines adopted by ASCO and NCCN.
Immunotherapy and Novel Combinations in PDAC
Investigated checkpoint inhibitors, cancer vaccines, and stromal-targeting agents in multiple early and late phase trials, systematically building knowledge of why PDAC is largely immunotherapy-resistant and identifying strategies to overcome this barrier.
Representative Works 代表性著作
Olaparib for Metastatic Germline BRCA-Mutated Pancreatic Cancer
New England Journal of Medicine (2019)
POLO trial demonstrating improved PFS with olaparib maintenance in BRCA1/2-mutated metastatic PDAC, the first biomarker-selected therapy approved in this disease.
Germline BRCA1/BRCA2 Mutations in Pancreatic Cancer: Clinical Implications and Management Recommendations
Journal of Clinical Oncology (2021)
Comprehensive review and expert recommendations on germline testing and clinical management of hereditary PDAC due to BRCA1/2 and related mutations.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 艾琳·奥赖利 的研究动态
Follow Eileen M. O'Reilly's research updates
留下邮箱，当我们发布与 Eileen M. O'Reilly（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment